132327-80-1 Usage
Description
Nalpha-Fmoc-Ndelta-trityl-L-glutamine, also known as Fmoc-Gln(Trt)-OH, is an amino acid derivative used in chemical synthesis and peptide chemistry. It is characterized by its good solubility properties in most organic solvents and is known for producing significantly purer peptides compared to other derivatives used for the introduction of glutamine. The trityl-protecting group can be removed by 95% TFA in 1-3 hours without causing alkylation of tryptophan.
Uses
Used in Chemical Synthesis:
Nalpha-Fmoc-Ndelta-trityl-L-glutamine is used as a building block for the synthesis of peptides and proteins. Its application is due to its good solubility and the ability to produce purer peptides, which is essential for the development of pharmaceuticals and other bioactive molecules.
Used in Peptide Chemistry:
In peptide chemistry, Nalpha-Fmoc-Ndelta-trityl-L-glutamine is used as a protected amino acid derivative for the stepwise synthesis of peptides. The trityl-protecting group allows for selective deprotection and coupling reactions, facilitating the assembly of complex peptide sequences with high purity and yield.
Used in Pharmaceutical Industry:
Nalpha-Fmoc-Ndelta-trityl-L-glutamine is used as a key component in the development of new drugs and therapeutic agents. Its role in peptide synthesis makes it a valuable tool for creating novel bioactive molecules with potential applications in various medical fields.
Used in Research and Development:
In the research and development sector, Nalpha-Fmoc-Ndelta-trityl-L-glutamine is used for the synthesis of custom peptides and proteins for various experimental purposes. Its high purity and solubility make it an ideal choice for scientific studies and the development of new biotechnological applications.
Check Digit Verification of cas no
The CAS Registry Mumber 132327-80-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,3,2 and 7 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 132327-80:
(8*1)+(7*3)+(6*2)+(5*3)+(4*2)+(3*7)+(2*8)+(1*0)=101
101 % 10 = 1
So 132327-80-1 is a valid CAS Registry Number.
InChI:InChI=1/C39H34N2O5/c42-36(41-39(27-14-4-1-5-15-27,28-16-6-2-7-17-28)29-18-8-3-9-19-29)25-24-35(37(43)44)40-38(45)46-26-34-32-22-12-10-20-30(32)31-21-11-13-23-33(31)34/h1-23,34-35H,24-26H2,(H,40,45)(H,41,42)(H,43,44)/t35-/m1/s1
132327-80-1Relevant articles and documents
Caged xanthones: Potent inhibitors of global predominant MRSA USA300
Chaiyakunvat, Pongkorn,Anantachoke, Natthinee,Reutrakul, Vichai,Jiarpinitnun, Chutima
, p. 2980 - 2983 (2016)
Total of 22 caged xanthones were subjected to susceptibility testing of global epidemic MRSA USA300. Natural morellic acid showed the strongest potency (MIC of 12.5 μM). However, its potent toxicity diminishes MRSA therapeutic potential. We synthetically modified natural morellic acid to yield 13 derivatives (3a-3m). Synthetically modified 3b retained strong potency in MRSA growth inhibition, yet the toxicity was 20-fold less than natural morellic acid, permitting the possibility of using caged xanthones for MRSA therapeutic.
NOVEL PEPTIDES DERIVED FROM NCAM (FGLs)
-
, (2011/05/05)
The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.
Antiangiogenic peptides
-
, (2008/06/13)
Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
